{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=91", "query": { "condition": "Lung Cancer", "page": 91 }, "page_size": 10 }, "pagination": { "page": 91, "page_size": 10, "total_count": 5928, "total_pages": 593, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=92&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=90&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T08:21:47.606Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03972228", "title": "Microdevice for Evaluating Drug Response in Site in Lung Lesions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lung Tumor", "Lung Cancer" ], "interventions": [ { "name": "Microdevice loaded with 19 chemotherapeutic agents", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Oliver Jonas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-10-01", "completion_date": "2021-09-01", "has_results": false, "last_update_posted_date": "2021-09-17", "last_synced_at": "2026-11-15T08:21:47.606Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03972228" }, { "nct_id": "NCT00843219", "title": "Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "PET/CT Scan", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2009-03", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-11-15T08:21:47.606Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00843219" }, { "nct_id": "NCT05501665", "title": "Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage III Lung Cancer" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan", "type": "OTHER" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-05-09", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-11-15T08:21:47.606Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05501665" }, { "nct_id": "NCT04924101", "title": "Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "Boserolimab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2021-07-15", "completion_date": "2025-06-23", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-11-15T08:21:47.606Z", "location_count": 14, "location_summary": "Gilbert, Arizona • Aurora, Colorado • Atlanta, Georgia + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04924101" }, { "nct_id": "NCT07772895", "title": "Pemefolacianine for IMI of Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer (Locally Advanced or Metastatic)" ], "interventions": [ { "name": "Pemefolacianine Cohort 1 in Part A", "type": "DRUG" }, { "name": "Pemefolacianin Cohort 2 in Part B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sunil Singhal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2026-03-11", "completion_date": "2027-03-11", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-11-15T08:21:47.606Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07772895" }, { "nct_id": "NCT05587439", "title": "Investigating Hereditary Risk In Thoracic Cancers (INHERIT)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer", "Genetic Disease", "Genetic Predisposition", "Hereditary Diseases" ], "interventions": [ { "name": "Data and Specimen Collection", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2023-01-01", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-11-15T08:21:47.606Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05587439" }, { "nct_id": "NCT01626001", "title": "Imaging Study Compare 4DCT Image", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophagus Cancer", "Lung Cancer" ], "interventions": [ { "name": "4D CT scans", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2012-07", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-11-15T08:21:47.606Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01626001" }, { "nct_id": "NCT04026412", "title": "A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 925, "start_date": "2019-10-08", "completion_date": "2024-11-26", "has_results": true, "last_update_posted_date": "2025-07-24", "last_synced_at": "2026-11-15T08:21:47.606Z", "location_count": 24, "location_summary": "La Jolla, California • San Francisco, California • Lone Tree, Colorado + 16 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04026412" }, { "nct_id": "NCT04507828", "title": "Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Close Proximity to the Chest Wall", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "Treatment Planning using the DIBH Technique", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2020-10-02", "completion_date": "2024-12-30", "has_results": false, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-11-15T08:21:47.606Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04507828" }, { "nct_id": "NCT03367819", "title": "Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Isatuximab SAR650984", "type": "DRUG" }, { "name": "Cemiplimab REGN2810", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2018-01-04", "completion_date": "2021-03-10", "has_results": true, "last_update_posted_date": "2022-05-16", "last_synced_at": "2026-11-15T08:21:47.606Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03367819" } ] }